NeoGenomics Files 8-K: Operations, Board & Officer Changes
Ticker: NEO · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1077183
Sentiment: neutral
Topics: corporate-governance, financial-results, executive-compensation
Related Tickers: NEO
TL;DR
NEO 8-K: Financials, board shakeup, exec comp details out.
AI Summary
On November 1, 2024, NeoGenomics, Inc. filed an 8-K report detailing significant corporate events. The filing includes information regarding the company's results of operations and financial condition, as well as changes in its board of directors and executive officers. It also covers compensatory arrangements for certain officers and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on NeoGenomics' financial performance and leadership structure, which are key indicators for investors assessing the company's stability and future direction.
Risk Assessment
Risk Level: medium — The filing addresses operational results and changes in leadership, which can introduce uncertainty and impact investor confidence.
Key Players & Entities
- NEOGENOMICS INC (company) — Registrant
- November 1, 2024 (date) — Date of earliest event reported
- 001-35756 (company) — Commission File Number
- 74-2897368 (company) — I.R.S. Employer Identification No.
- 9490 NeoGenomics Way, Fort Myers, Florida 33912 (company) — Address of principal executive offices
- (239) 768-0600 (company) — Registrant's telephone number
FAQ
What specific financial information is being disclosed in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', suggesting a disclosure of financial performance and related documents.
What changes are reported regarding NeoGenomics' directors or officers?
The filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of disclosure.
Are there any details on executive compensation provided in this report?
Yes, the filing mentions 'Compensatory Arrangements of Certain Officers' as a topic covered.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is November 1, 2024.
What is NeoGenomics' state of incorporation and fiscal year end?
NeoGenomics, Inc. is incorporated in Nevada and its fiscal year ends on December 31.
Filing Stats: 696 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-05 07:14:34
Key Financial Figures
- $0.001 — ange on which registered Common stock ($0.001 par value) NEO The Nasdaq Stock Market
- $140,000 — nitial equity award worth approximately $140,000, $98,000 of which will be in the form o
- $98,000 — ity award worth approximately $140,000, $98,000 of which will be in the form of restric
- $42,000 — be in the form of restricted stock and $42,000 of which will be in the form of stock o
Filing Documents
- neo-20241101.htm (8-K) — 33KB
- a99-109302024earningsrelea.htm (EX-99.1) — 425KB
- earnings_header002.jpg (GRAPHIC) — 100KB
- 0001077183-24-000153.txt ( ) — 748KB
- neo-20241101.xsd (EX-101.SCH) — 2KB
- neo-20241101_lab.xml (EX-101.LAB) — 22KB
- neo-20241101_pre.xml (EX-101.PRE) — 13KB
- neo-20241101_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 5, 2024, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board of Director Appointment On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company's Audit and Finance Committee (the "Audit Committee") and the Company's Nominating and Corporate Governance Committee (the "NCG Committee"). Ms. Williams will serve as a member of the Board until the 2025 annual meeting of shareholders of the Company or until her resignation or removal and otherwise until her successor is elected. Ms. Williams received an initial equity award worth approximately $140,000, $98,000 of which will be in the form of restricted stock and $42,000 of which will be in the form of stock options, both of which shall vest on June 1, 2025. Ms. Williams will also receive compensation for her service as member of the Board, Audit Committee and NCG Committee consistent with the Company's independent director compensation program previously disclosed in the Company's definitive proxy statement for its 2024 annual meeting of shareholders. Ms. Williams does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 99.1 Press Release of NeoGenomics, Inc. dated November 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. By: /s/ Jeffrey S. Sherman Name: Jeffrey S. Sherman Title: Chief Financial Officer Date: November 5, 2024